Since 2007, Hangzhou Huadong Pharmaceutical Group Co., Ltd. has adapted to the times, carried out reforms in personnel, finance and materials, and adjusted its product structure according to market requirements. Pay attention to the all-round development of production, marketing, scientific research and management, and people and enterprises live in harmony. In April, the rectification centered on "emancipating the mind, changing ideas, breaking superstitions and raising awareness" was carried out to promote the sustained and rapid development of East China Pharmaceutical Group.
Huadong Pharmaceutical Group became the meritorious enterprise of "revitalizing the city through industry" from 2004 to 2006, and won the title of "Top Ten Outstanding Industrial Enterprises" in Hangzhou for three consecutive years, and the title of "revitalizing the city through industry" in Hangzhou in 2006 and 2007. In 2008, the Group won the title of "Meritorious Enterprise for Revitalizing the City through Industry" in Hangzhou again, and Li Bangliang, the chairman of the Group, won the title of "Excellent Operator of Meritorious Enterprise for Revitalizing the City through Industry" in Hangzhou.
Huadong Pharmaceutical Group ranks among the top 500 manufacturing enterprises in China. Since China Entrepreneur Association and China Entrepreneur Association released the list of the top 500 manufacturing enterprises in China in 2005, Huadong Pharmaceutical Group has been on the list every year. In 2008, referring to international practice, the China Entrepreneurs' Federation and the China Entrepreneurs' Association selected the top 500 manufacturing enterprises in China for the fourth time with the sales revenue of enterprises reaching 3 billion yuan in 2007 as the shortlisting standard, and were recognized by the expert committee. Huadong Pharmaceutical Group is on the list, ranking 363rd.
The first phase project of Oriental Huayi Pharmaceutical Co., Ltd. was completed. Esteve Huayi Pharmaceutical Co., Ltd. is a subsidiary of Hangzhou Huadong Pharmaceutical Group Co., Ltd., located in Paojiang Industrial Park, Shaoxing, Zhejiang Province, mainly engaged in the research and development, production and sales of generic drugs. It covers an area of 6.5438+0.32 million square meters, and the land for the first phase is 80,000 square meters. The total investment is 46 million USD, and the registered capital is170,000 USD. In March 2008, the first phase of the company's main project was completed, and the whole project is scheduled to be completed and put into use by the end of 2009.
In April, Huadong Pharmaceutical Co., Ltd., the largest member of Huadong Pharmaceutical Group, invested 98 million yuan to acquire 78.87% equity of Xi Anbohua Pharmaceutical Co., Ltd. and 65% equity of Shaanxi Jiuzhou Pharmaceutical Co., Ltd. This merger and acquisition is an action taken by East China Pharmaceutical Company to adjust the product structure and accelerate the strategic layout adjustment of some APIs and chemical intermediates, which meets the needs of opening up the international market and helps to achieve new expansion in the field of characteristic APIs (gynecological drugs) and anesthetics.
New drug development East China Pharmaceutical Group adheres to the principle of paying equal attention to raw materials and preparations, international market and domestic market, and technology and management, and insists on focusing on one industry, constantly developing new products, consolidating and expanding the domestic market, and exploring and integrating into the international market. In September, the GMP management process of tacrolimus, an immunosuppressant product newly developed by the Institute of Bioengineering of East China Pharmaceutical Group, officially passed the on-site inspection of the US FDA, and successfully obtained the approval for the production of raw materials and preparations, thus obtaining the access protection for the products to open the US market. In August, Kang Run Pharmaceutical Co., Ltd. obtained the production license of Shu Jing huoxue capsule, an orthopedic medicine. In June+February, 5438, the first chemical medicine of Hangzhou Jiuyuan Genetic Engineering Co., Ltd.-Panosetron hydrochloride antiemetic drug was officially listed.
Six enterprises have become national high-tech enterprises. In 2008, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Jiuyuan Genetic Engineering Co., Ltd., Zhejiang Huayi Pharmaceutical Co., Ltd., Huadong Pharmaceutical Group Bioengineering Research Institute Co., Ltd., Hangzhou Zhuyangxin Pharmaceutical Co., Ltd. and Huadong Pharmaceutical Group Kang Run Pharmaceutical Co., Ltd. passed the national high-tech enterprise certification assessed by the Ministry of Science and Technology.